Home  »  Business   »  Y-mAbs Therapeutics Inc. (NASDAQ: YMAB): Getting A...

Y-mAbs Therapeutics Inc. (NASDAQ: YMAB): Getting A Free Pass?

Y-mAbs Therapeutics Inc. (NASDAQ:YMAB) shares, rose in value on Thursday, 05/12/22, with the stock price up by 6.08% to the previous day’s close as strong demand from buyers drove the stock to $8.90.

Actively observing the price movement in the last trading, the stock closed the session at $8.39, falling within a range of $7.32 and $8.91. The value of beta (5-year monthly) was 1.29. Referring to stock’s 52-week performance, its high was $39.82, and the low was $6.50. On the whole, YMAB has fluctuated by -30.58% over the past month.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '22.
Small-cap Uranium stocks are booming in 2022! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.


With the market capitalization of Y-mAbs Therapeutics Inc. currently standing at about $410.11 million, investors are eagerly awaiting this quarter’s results, scheduled for Feb 23, 2022 – Feb 28, 2022. As a result, investors might want to see an improvement in the stock’s price before the company announces its earnings report. Analysts are projecting the company’s earnings per share (EPS) to be -$0.68, which is expected to increase to -$0.51 for fiscal year -$1.13 and then to about -$1 by fiscal year 2022. Data indicates that the EPS growth is expected to be 62.00% in 2022, while the next year’s EPS growth is forecast to be 11.50%.

Analysts have estimated the company’s revenue for the quarter at $11.12 million, with a low estimate of $10 million and a high estimate of $12.83 million. According to the average forecast, sales growth in current quarter could jump down -46.40%, compared to the corresponding quarter of last year. Wall Street analysts also predicted that in 2022, the company’s y-o-y revenues would reach $35.95 million, representing an increase of 73.30% from the revenues reported in the last year’s results.

Revisions could be a useful indicator to get insight on short-term price movement; so for the company, there were no upward and no downward review(s) in last seven days. We see that YMAB’s technical picture suggests that short-term indicators denote the stock is a 100% Sell on average. However, medium term indicators have put the stock in the category of 100% Sell while long term indicators on average have been pointing out that it is a 100% Sell.

The stock’s technical analysis shows that the PEG ratio is about 0, with the price of YMAB currently trading nearly -13.61% and -17.90% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 43.08, while the 7-day volatility ratio is showing 16.63% which for the 30-day chart, stands at 11.54%. Furthermore, Y-mAbs Therapeutics Inc. (YMAB)’s beta value is 1.49, and its average true range (ATR) is 1.10. The company’s stock has been forecasted to trade at an average price of $27.14 over the course of the next 52 weeks, with a low of $15.00 and a high of $63.00. Based on these price targets, the low is -68.54% off current price, whereas the price has to move -607.87% to reach the yearly target high. Additionally, analysts’ median price of $21.00 is likely to be welcomed by investors because it represents a decrease of -135.96% from the current levels.

Data on historical trading for Y-mAbs Therapeutics Inc. (NASDAQ:YMAB) indicates that the trading volumes over the past 10 days have averaged 0.77 million and over the past 3 months, they’ve averaged 539.01K. According to company’s latest data on outstanding shares, there are 43.67 million shares outstanding.

Nearly 0.50% of Y-mAbs Therapeutics Inc.’s shares belong to company insiders and institutional investors own 64.00% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 2.57 million shares as on Feb 14, 2022, resulting in a short ratio of 1.78. According to the data, the short interest in Y-mAbs Therapeutics Inc. (YMAB) stood at 5.89% of shares outstanding as of Feb 14, 2022; the number of short shares registered in Jan 13, 2022 reached 1.96 million. The stock has fallen by -45.10% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the YMAB stock heading into the next quarter.

Leave a Comment

Your email address will not be published.

Related Videos

Related Posts



Download Free eBook For


100% free. stop anytime no spam